This website uses cookies to enhance the user experience.
E

ECCELODIUS AS928 489 566

Research
Limited company
Jernbaneveien 45 1369 STABEKK, Norge

ECCELODIUS AS

Keywords

researchdevelopment worknatural sciencesengineeringtechnologymedicineagricultureinterdisciplinary research

Organization

CEO
ÅE
Chairman of the board
ÅE
Years since formation
2 years
since Jan 5, 2022
Type
Limited company
VAT registered
No
Number of employees
0

Ownership

Number of shares and share classes
3,000
1 share class
Total number of shareholders
1
person
Belongs to group of

Financials

Annual total result 2023
-19,668
NOK
Total equity 2023
4,762
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
ÅE
Managing Director/CEO
100 %
directly

Board

NameRoleShares
ÅE
Chairman
100 %
directly

Others

NameRoleShares
S
SKOGVOLD REGNSKAP
Accountant-

Top 10 individual shareholders

NameRoleShares
ÅE
Managing Director/CEO, Chairman
100 %
directly
Last update: Sep 4, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
ÅE
A-shares
3,000
100 %

Shares owned by the ECCELODIUS AS

NameShare classNumber of sharesShare
E
ECCELUDE AS
A-shares
3,000
100 %
H
HUMENO AS
Ordinary shares
15,000
50 %
C
CROESUS INVEST AS
Ordinary shares
15,000
50 %
C
COSGEAR AS
Ordinary shares
200
0.04 %
I
ILAG AS
Ordinary shares
50
0.03 %
A
ALV B AS
Ordinary shares
1,692
0.03 %
B
BOOKIS SPV AS
Ordinary shares
20
0.03 %
P
PHARMASUM THERAPEUTICS AS
Ordinary shares
500
0.02 %
S
SULTEN AS
Ordinary shares
3,335
0.02 %
A
ALOTTA AS
Ordinary shares
20
< 0.01 %
F
FOLKEKRAFT AS
Ordinary shares
100
< 0.01 %
NO0010813843
4,000
< 0.01 %
L
LEDIDI AS
Ordinary shares
150
< 0.01 %
B
BRAVO MARINE AS
Ordinary shares
45
< 0.01 %
M
MARINE PRO AS
Ordinary shares
2,000
< 0.01 %
A
AUK ECO AS
Ordinary shares
110
< 0.01 %
L
LØPETRENING AS
Ordinary shares
16
< 0.01 %
D
DRIBBLR GROUP AS
Ordinary shares
53
< 0.01 %
I
INSULIFE AS
NO0012753625
3,333
< 0.01 %
S
SALMON EVOLUTION ASA
NO0010892094
400
< 0.01 %
F
FLYR AS
NO0010931900
33,000
< 0.01 %
N
NORDIC SEMICONDUCTOR ASA
NO0003055501
20
< 0.01 %
L
LYTIX BIOPHARMA AS
NO0010405780
100
< 0.01 %
B
BERGENBIO ASA
NO0010650013
5,000
< 0.01 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 0
    Operating profit 2023: NOK -19,315
    Employees: 0

Financials

in NOK

Summary

Year20232022
Total operating income
0
0
Annual Total Result
-19,668
0
Total assets
308,800
127,945
Total liabilities
304,038
103,515
Total equity
4,762
24,430

P&L

Year20232022
Total operating income
0
0
Total operating costs
19,315
15,770
Operating result
-19,315
-15,770
Financial income/costs
-353
15,770
Profit before tax
-19,668
0
Total tax & extraordinary income/cost
0
0
Annual Total Result
-19,668
0

Balance overview

Year20232022
Total fixed assets
30,000
30,000
Total current assets
278,800
97,945
Total assets
308,800
127,945
Short term debt
304,038
103,515
Long term debt
0
0
Total liabilities
304,038
103,515
Contributed capital
24,430
24,430
Retained earnings
-19,668
0
Total equity
4,762
24,430
Total equity and liabilities
308,800
127,945

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.19
Industrial group
Other research and experimental development on natural sciences and engineering
72.190
Industrial group
Other research and experimental development on natural sciences and engineering